Previous close | 28.27 |
Open | 28.57 |
Bid | 28.17 x 100 |
Ask | 28.28 x 100 |
Day's range | 27.94 - 28.76 |
52-week range | 13.72 - 33.34 |
Volume | |
Avg. volume | 554,308 |
Market cap | 1.656B |
Beta (5Y monthly) | 2.08 |
PE ratio (TTM) | 11.11 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Comprehensive Analysis of Q1 2024 Earnings and Strategic Developments
With the business potentially at an important milestone, we thought we'd take a closer look at Protagonist...
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.